ANG Lifesciences India Ltd
Ticker: ANG
Decent
56/100
☆ Add to Watchlist
Investing Reference
Price
30.77
Market Cap
40.18
Debt/Equity
1.3006
ROE %
-17.681
PB
0.6280
Promoter %
70.603
Pledge %
31.685
1Y Rev Growth %
-35.379
5Y Rev Growth %
NP Margin %
-13.071
NP Margin 5Y Avg %
-0.866
Trading Reference
1M Return %
-7.468
6M Return %
6.581
1Y Return %
-37.675
% Away 52W High
64.803
% Away 52W Low
46.315
Daily Volume
5593
Investment Verdict
Risky
Score 57/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 8/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
ANG Lifesciences India Ltd is currently trading near a strong support level, with the 50-day EMA indicating bullish momentum. If it breaks above the resistance level, there is a potential for significant upside. However, if it fails to hold the support, downside risk remains.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
T
Travels & Rentals Ltd
Travels & Rentals Ltd operates in a promising sector, but faces significant challenges in growth consistency and profitability, making it a risky investment at this time.
View details
M
Mono Pharmacare Ltd
Mono Pharmacare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Abm International Ltd
Abm International Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
AIK Pipes and Polymers Ltd
AIK Pipes and Polymers Ltd shows potential in a growing sector, but faces challenges in consistency and valuation. Caution is advised.
View details
L
Laxmi Cotspin Ltd
Laxmi Cotspin Ltd shows potential in a growing sector but faces challenges in execution and profitability consistency.
View details
F
Future Enterprises Ltd
Future Enterprises Ltd presents significant risks with inconsistent growth and profitability metrics, alongside a challenging market environment.
View details
J
Johnson Pharmacare Ltd
Johnson Pharmacare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Advance Metering Technology Ltd
Advance Metering Technology Ltd shows potential in a growing sector, but faces challenges in execution and market competition.
View details
E
Ecofinity Atomix Ltd
Ecofinity Atomix Ltd shows potential but faces significant challenges in growth consistency and profitability metrics.
View details
D
Duropack Ltd
Duropack Ltd shows several weaknesses in growth, profitability, and market sentiment, making it a risky investment at this time.
View details
P
Picturehouse Media Ltd
Picturehouse Media Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
H
Hind Aluminium Industries Ltd
Hind Aluminium Industries Ltd shows potential in a growing sector, but faces challenges in consistent growth and market sentiment.
View details
W
West Leisure Resorts Ltd
West Leisure Resorts Ltd shows potential but faces several challenges that may hinder growth and profitability.
View details
S
Shreeshay Engineers Ltd
Shreeshay Engineers Ltd shows potential in a future-ready sector but faces significant challenges in growth and profitability metrics, making it a risky investment at this time.
View details
T
Tirupati Sarjan Ltd
Tirupati Sarjan Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
F
Fortune International Ltd
Fortune International Ltd shows moderate potential but faces several challenges that could impact future performance.
View details
Business Overview
ANG Lifesciences India Ltd is a leading player in the Indian pharmaceutical sector, specializing in the development and manufacturing of high-quality APIs and formulations. Catering to both domestic and international markets, the company focuses on innovative healthcare solutions that improve patient outcomes. With a commitment to quality and compliance, ANG Lifesciences is poised for growth in a rapidly evolving industry.
- Established expertise in pharmaceuticals
- Focus on high-quality APIs and formulations
- Strong domestic and international presence
- Commitment to innovation and patient care
- Robust compliance with industry standards
Investment Thesis
ANG Lifesciences India Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This positions the company for sustainable growth in the evolving healthcare landscape.
- Promoter group with a proven track record enhances investor confidence.
- Robust growth potential in digital healthcare services aligns with market trends.
- Valuation metrics indicate ANG is undervalued relative to industry peers.
- Strong fundamentals support long-term growth and profitability.
- Strategic focus on innovation and technology positions ANG for future success.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare solutions
- Strong pipeline of innovative products
- Expansion into international markets
- Partnerships with leading healthcare firms
Risks ⚠️
- Regulatory changes affecting operations
- High competition in the industry
- Fluctuating raw material costs
- Dependence on key management personnel
Peer Perspective
ANG Lifesciences India Ltd trades at a discount compared to peers like Biocon and Dr. Reddy's, primarily due to margin volatility; a stable margin profile could trigger a rerating in its valuation.
Future Outlook
ANG Lifesciences India Ltd is well-positioned for growth, driven by innovative product development and expanding market reach; however, successful execution and effective cost management will be crucial to achieving its strategic objectives.
AI FAQs for Retail Users
- Q: What does ANG Lifesciences India Ltd do?A: ANG Lifesciences focuses on pharmaceutical and biotechnology solutions, including drug development and manufacturing.
- Q: Is ANG Lifesciences a profitable company?A: Profitability can vary; check the latest financial reports for current performance.
- Q: What are the risks of investing in ANG Lifesciences?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of ANG Lifesciences?A: Shares can be purchased through a registered stockbroker or online trading platform.
- Q: What should I consider before investing in ANG Lifesciences?A: Consider financial health, market position, and industry trends before making an investment decision.
📊 Stock Investment Checklist (100 Points)
ANG Lifesciences India Ltd • Updated: 2025-09-17 01:13:19
-
10BusinessHighThe sector is growing with increasing demand for healthcare solutions, but competitive pressures exist.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent compared to net profit.
-
8ValuationHighValuation metrics are slightly above industry averages, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios are on the lower side.
-
6GovernanceGoodPromoter holding is stable, but there are concerns regarding pledging.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 56 / 100
• Decent
ANG Lifesciences India Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 68/100